Paper Details

  1. Home
  2. Paper Details

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.

Author: AntelopeOrlando, DeiningerMichael W, EiringAnna M, KelleyTodd W, KovacsovicsTibor J, O'HareThomas, PatelAmi B, PomicterAnthony D, SchumacherJonathan A, ShamiPaul J, TantravahiSrinivas K, YanDongqing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

FLT3-ITD mutations are associated with aggressive AML and can lead to resistance to FLT3 inhibitors. This study found that bone marrow microenvironment contributes to resistance and that combining quizartinib with dasatinib might overcome this resistance.
Paper Details　
Original Abstract of the Article :
FLT3-ITD mutations occur in 20-30% of AML patients and are associated with aggressive disease. Patients with relapsed FLT3-mutated disease respond well to 2nd generation FLT3 TKIs but inevitably relapse within a short timeframe. In this setting, until overt relapse occurs, the bone marrow microenvir...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32409689

データ提供：米国国立医学図書館（NLM）

Overcoming Stroma-Based Resistance in AML: A New Path Forward

This research delves into the complex world of acute myeloid leukemia (AML), focusing on the challenge of overcoming resistance to FLT3 inhibitors, a type of medication used to treat this aggressive form of cancer. Imagine this research as a journey through a vast desert of cancer research, searching for new ways to combat this deadly disease. The authors investigate the potential of combining quizartinib, a FLT3 inhibitor, with dasatinib, a drug that targets a different pathway involved in leukemia cell growth. They explore the mechanisms by which this combination therapy overcomes resistance and improves treatment outcomes.

Finding a New Oasis in the Desert of Resistance

The study reveals that dasatinib can overcome stroma-based resistance to quizartinib by inhibiting the activation of STAT5, a signaling pathway that promotes leukemia cell survival. Imagine finding a hidden oasis in the midst of a vast desert, providing a new source of life and hope. This research highlights the potential of combining different medications to target multiple pathways involved in cancer cell growth, potentially leading to more effective treatments.

A Collaborative Approach to Fighting Leukemia

This research underscores the importance of a collaborative approach to treating leukemia. Imagine a team of explorers working together to overcome the challenges of the desert. The study highlights the need for researchers and clinicians to work together to develop and refine new combination therapies. This research serves as a reminder that the fight against cancer requires a multi-pronged approach and a united front.

Dr.Camel's Conclusion

This research offers a glimmer of hope in the fight against AML, highlighting the potential of a combination therapy to overcome resistance to FLT3 inhibitors. The study emphasizes the importance of a collaborative approach to research and clinical practice, working together to find new solutions for patients facing this challenging disease. Just as a traveler in the desert relies on the support of others, the fight against cancer requires a collective effort to find the path to healing.

Date :
  1. Date Completed 2020-11-30
  2. Date Revised 2022-04-18
Further Info :

Pubmed ID

32409689

DOI: Digital Object Identifier

NIHMS1589983

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.